RT Journal Article
SR Electronic
T1 Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.30.20048108
DO 10.1101/2020.03.30.20048108
A1 Vogels, Chantal B.F.
A1 Brito, Anderson F.
A1 Wyllie, Anne L.
A1 Fauver, Joseph R.
A1 Ott, Isabel M.
A1 Kalinich, Chaney C.
A1 Petrone, Mary E.
A1 Casanovas-Massana, Arnau
A1 Muenker, M. Catherine
A1 Moore, Adam J.
A1 Klein, Jonathan
A1 Lu, Peiwen
A1 Lu-Culligan, Alice
A1 Jiang, Xiaodong
A1 Kim, Daniel J.
A1 Kudo, Eriko
A1 Mao, Tianyang
A1 Moriyama, Miyu
A1 Oh, Ji Eun
A1 Park, Annsea
A1 Silva, Julio
A1 Song, Eric
A1 Takahashi, Takehiro
A1 Taura, Manabu
A1 Tokuyama, Maria
A1 Venkataraman, Arvind
A1 Weizman, Orr-El
A1 Wong, Patrick
A1 Yang, Yexin
A1 Cheemarla, Nagarjuna R.
A1 White, Elizabeth B.
A1 Lapidus, Sarah
A1 Earnest, Rebecca
A1 Geng, Bertie
A1 Vijayakumar, Pavithra
A1 Odio, Camila
A1 Fournier, John
A1 Bermejo, Santos
A1 Farhadian, Shelli
A1 Dela Cruz, Charles S.
A1 Iwasaki, Akiko
A1 Ko, Albert I.
A1 Landry, Marie L.
A1 Foxman, Ellen F.
A1 Grubaugh, Nathan D.
YR 2020
UL http://medrxiv.org/content/early/2020/04/26/2020.03.30.20048108.abstract
AB The recent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exemplifies the critical need for accurate and rapid diagnostic assays to prompt clinical and public health interventions. Currently, several quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assays are being used by clinical, research, and public health laboratories. However, it is currently unclear if results from different tests are comparable. Our goal was to evaluate the primer-probe sets used in four common diagnostic assays available on the World Health Organization (WHO) website. To facilitate this effort, we generated RNA transcripts to be used as assay standards and distributed them to other laboratories for internal validation. We then used (1) RNA transcript standards, (2) full-length SARS-CoV-2 RNA, (3) pre-COVID-19 nasopharyngeal swabs, and (4) clinical samples from COVID-19 patients to determine analytical efficiency and sensitivity of the qRT-PCR primer-probe sets. We show that all primer-probe sets can be used to detect SARS-CoV-2 at 500 virus copies per reaction, except for the RdRp-SARSr (Charité) confirmatory primer-probe set which has low sensitivity. Our findings characterize the limitations of currently used primer-probe sets and can assist other laboratories in selecting appropriate assays for the detection of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the generous support from the Yale Institute for Global Health and the Yale School of Public Health start-up package provided to NDG. CBFV is supported by NWO Rubicon 019.181EN.004. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in this article and the supplemental files.